Study group

Female (%)

Median age (min to max, years)

Preoperative median BCVA (min to max, logMAR)

Axial length (mean ± SD, mm)

Postoperative follow-up months (median, range)

Control emmetropic group (n = 25)

76

52 (22 to 66)

0.00 (−0.12 to 0.09)

20.53 ± 0.09

-

Control myopic group (n = 20)

70

60 (48 to 70)

0.00 (0.00 to 0.09)

29.45 ± 1.49

-

Surgical treatment group (N=46)

Stage 1 (n = 5)

84.6

59 (44 to 70)

0.69 (0.60 to 1.00)

30.54 ± 1.51

13 (6 - 58)

Stage 2 (n = 26)

75.4

59 (43 to 76)

1.00 (0.60 To 1.30)

29.38 ± 1.64

27 (6 - 67)

Stage 3 (n = 4)

90

61 (46 to 70)

1.15 (0.54 to 1.30)

30.10 ± 1.33

15.50 (6 - 62)

Stage 4 (n = 11)

71.4

58 (43 to 82)

1.30 (0.60 to 1.30)

29.94 ± 1.71

40 (6 - 67)